cell
cell
obtain
american
type
cultur
collect
cell
bank
chines
academi
scienc
respect
strain
merscov
passag
design
merscov
provid
dr
bart
haagman
ron
fouchier
emc
passag
vero
cell
adenoviru
serotyp
develop
propag
univers
iowa
gene
transfer
vector
core
circular
dichroism
spectroscopi
use
determin
secondari
structur
peptid
complex
describ
elsewher
analysi
thermal
denatur
peptid
complex
immedi
monitor
use
sampl
nm
thermal
gradient
valu
degre
taken
content
data
process
use
jasco
softwar
nativ
polyacrylamid
gel
electrophoresi
npage
perform
describ
elsewher
peptid
phosphatebuff
salin
pb
incub
peptid
minut
respect
use
pb
control
follow
load
trisglycin
gel
tricin
glycin
run
buffer
ph
stain
coomassi
blue
imag
acquir
fluorchem
imag
system
alpha
innotechproteinsimpl
fluoresc
npage
fnpage
carri
manner
describ
npage
except
use
fluorescein
peptid
peptid
respect
pb
incub
peptid
minut
form
incub
increas
concentr
pb
minut
addit
follow
incub
anoth
minut
inhibit
format
gel
imag
use
fluorchem
imag
system
excit
wavelength
nm
emiss
wavelength
nm
imag
gel
stain
coomassi
blue
reimag
merscov
cellcel
fusion
test
describ
elsewher
cell
transfect
plasmid
paaviresmersegfp
respect
coexpress
merscov
protein
egfp
cell
surfac
use
effector
cell
wherea
cell
express
egfp
use
neg
control
cell
cell
incub
cell
express
merscov
receptor
target
cell
absenc
presenc
test
peptid
indic
concentr
hour
cell
fuse
unfus
cell
count
invert
fluoresc
microscop
nikon
eclips
ti
median
inhibitori
concentr
calcul
use
calcusyn
softwar
pseudovirus
carri
merscov
protein
without
mutat
produc
describ
elsewher
briefli
pseudoviru
incub
test
peptid
grade
concentr
hour
follow
addit
viruspeptid
mixtur
cell
cultur
refe
fresh
medium
hour
infect
incub
anoth
hour
follow
addit
luciferas
substrat
promega
fluoresc
assess
use
luciferas
kit
promega
ultra
luminomet
tecan
specif
pathogenfre
mice
mice
purchas
nation
cancer
institut
jackson
laboratori
respect
bred
univers
iowa
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
anim
experi
approv
institut
anim
care
use
committe
univers
iowa
protocol
mice
transduc
intranas
plaqueform
unit
pfu
dulbecco
modifi
eagl
medium
dmem
five
day
transduct
mice
infect
intranas
wildtyp
wt
mutant
merscov
dmem
treat
intranas
pb
peptid
alon
combin
work
merscov
conduct
univers
iowa
biosafeti
level
laboratori
lung
viral
titer
determin
use
vero
cell
describ
elsewher
viral
titer
express
plaqueform
unit
per
gram
lung
tissu
recombin
bacteri
artifici
chromosom
bac
mutat
engin
use
kanriscei
marker
cassett
posit
neg
select
describ
elsewher
pbacmerscov
gener
gift
lui
enjuan
transform
escherichia
coli
cell
gener
gift
greg
smith
contain
arabinoseinduc
iscei
restrict
enzym
polymeras
chain
reaction
product
gener
transform
cell
recombin
pbacmerscov
recombin
bac
select
plate
verifi
restrict
enzym
digest
polymeras
chain
reaction
result
bac
clone
term
pbacmerscov
test
inhibitori
activ
peptid
variant
figur
merscov
cellcel
fusion
use
control
peptid
mer
sar
deriv
domain
merscov
sarscov
protein
respect
strongli
inhibit
cellcel
fusion
dosedepend
manner
valu
respect
figur
indic
improv
membran
fusion
inhibitori
activ
compar
sar
peptid
inhibit
merscov
cellcel
fusion
concentr
confirm
previou
observ
lu
et
al
merscov
protein
domain
target
site
peptid
eg
larg
conserv
sequenc
differ
strain
compar
among
clinic
merscov
strain
amino
acid
chang
posit
domain
figur
observ
present
nearli
strain
test
whether
effect
merscov
strain
compar
inhibitori
activ
cellcel
fusion
mediat
merscov
protein
without
mutat
surprisingli
potent
inhibit
cellcel
fusion
mediat
merscov
protein
bear
respect
wt
protein
strain
figur
subsequ
compar
sar
inhibitori
activ
entri
pseudoviru
express
merscov
protein
shown
figur
also
potent
valu
respect
wherea
exhibit
inhibit
concentr
construct
pseudovirus
express
merscov
protein
mutat
compar
sensit
similarli
effect
inhibit
infect
pseudovirus
carri
mutant
protein
infect
pseudoviru
carri
wt
protein
wherea
display
inhibit
either
mutant
merscov
pseudoviru
figur
result
suggest
expect
effect
merscov
strain
isol
far
lu
et
al
show
previous
peptid
deriv
merscov
protein
domain
respect
could
interact
togeth
form
stabl
complex
approxim
thermal
unfold
transit
tm
valu
use
circular
dichroism
spectroscopi
compar
secondari
structur
mutant
complex
form
peptid
shown
figur
show
low
approxim
wherea
peptid
display
random
structur
howev
complex
form
peptid
exhibit
structur
rang
figur
addit
high
tm
valu
figur
suggest
interact
peptid
form
highli
stabl
complex
use
npage
fnpage
investig
interact
mutant
result
shown
figur
alon
detect
gel
figur
lane
peptid
carri
net
posit
charg
thu
migrat
gel
nativ
electrophoresi
condit
alon
migrat
rapidli
lane
wherea
mixtur
mutant
migrat
slowli
gel
lane
similarli
alon
exhibit
rapidli
migrat
band
lane
wherea
mixtur
mutant
migrat
slowli
gel
lane
result
confirm
interact
mutant
form
subsequ
assess
abil
inhibit
format
merscov
peptid
use
fnpage
describ
elsewher
shown
figur
sampl
contain
lane
display
singl
fluoresc
band
locat
lower
portion
gel
wherea
mixtur
lane
migrat
slowli
band
correspond
increas
concentr
incub
minut
addit
lane
fluoresc
intens
band
gradual
increas
wherea
band
complex
correspond
decreas
suggest
inhibit
format
dosedepend
manner
mice
impervi
infect
merscov
sensit
infect
transduct
test
vivo
efficaci
infect
merscov
recombin
merscov
carri
mutat
protein
pb
control
intranas
administ
mice
hour
challeng
pfu
merscov
total
dmem
volum
shown
figur
viral
titer
lung
pbstreat
mice
challeng
recombin
merscov
carri
wt
protein
peak
pfusg
respect
strikingli
titer
lung
mice
treat
challeng
wt
merscov
decreas
pfusg
wt
limit
detect
repres
reduct
viral
titer
lung
limit
detect
viral
titer
assay
pfusg
suggest
mice
intranas
treat
hour
challeng
merscov
variant
highli
protect
merscov
infect
studi
use
hivspecif
peptid
enfuvirtid
demonstr
emerg
resist
domain
hiv
prolong
exposur
therefor
diminish
likelihood
occurr
provid
addit
layer
protect
event
emerg
resist
viru
includ
prophylact
therapeut
regimen
potent
inhibit
merscov
infect
cell
cultur
zhao
et
al
show
previous
treatment
merscov
challeng
significantli
acceler
kinet
viru
clearanc
initi
test
vivo
efficaci
combin
prophylaxi
mice
mice
transduc
treat
day
later
intranas
administr
pb
six
hour
later
mice
challeng
merscov
viral
titer
measur
hour
infect
titer
significantli
reduc
treat
group
complet
clearanc
observ
mice
treat
figur
assess
whether
drug
could
use
therapeut
mice
treat
hour
infect
pb
viral
titer
measur
hour
infect
shown
figur
titer
significantli
decreas
inhibitortr
group
p
comparison
pbstreat
group
greatest
reduct
observ
mice
moreov
treatment
alon
result
signific
reduct
viral
titer
comparison
alon
treatment
group
figur
b
addit
cohort
control
mice
mice
treat
therapeut
kill
day
infect
lung
examin
histolog
chang
agreement
previou
report
lung
mice
show
perivascular
peribronchi
interstiti
infiltr
well
alveolar
septa
thicken
howev
infiltr
moder
reduc
mice
treat
alon
patholog
chang
attenu
group
consist
effect
viral
titer
figur
instanc
signific
eosinophil
infiltr
detect
mice
lack
b
cell
recombin
activ
gene
unabl
clear
merscov
viru
detect
lung
day
data
shown
therefor
determin
whether
could
enhanc
viru
clearanc
absenc
adapt
immun
respons
mice
treat
prophylact
therapeut
describ
mice
prophylact
treatment
result
enhanc
viru
clearanc
hour
infect
complet
viru
clearanc
mice
figur
similarli
measur
viral
titer
hour
infect
follow
therapeut
treatment
hour
reveal
signific
decreas
titer
treatment
p
vs
pb
treatment
viral
titer
reduc
mice
treat
figur
previou
studi
demonstr
peptid
deriv
merscov
protein
potent
inhibit
viru
entri
present
studi
first
show
peptid
function
infect
lung
result
conclud
peptid
stabl
milieu
lung
intranas
administr
deliv
peptid
area
infect
suffici
quantiti
inhibit
viru
entri
far
specif
antivir
drug
develop
prevent
treat
merscov
infect
falzarano
et
al
demonstr
combin
ribavirin
administ
rhesu
macaqu
within
hour
inocul
merscov
result
benefici
effect
reduc
viru
replic
lung
injuri
inflamm
thu
improv
clinic
outcom
combin
also
provid
sever
sever
ill
patient
though
reduc
mortal
rate
day
treatment
show
benefici
effect
day
possibl
late
administr
combin
may
diminish
morbid
mortal
rate
success
either
therapi
alon
recent
sever
compound
food
drug
drug
librari
report
inhibitori
activ
merscov
replic
cell
cultur
liu
et
al
demonstr
merscov
replic
inhibitor
could
inhibit
clathrinmedi
endocytosi
inhibit
merscov
membran
fusion
none
abl
inhibit
format
therefor
smallmolecul
merscov
replic
inhibitor
seem
mechan
action
differ
peptid
merscov
fusion
inhibitor
domain
merscov
protein
import
target
develop
merscov
fusion
inhibitor
region
rel
conserv
singl
chang
amino
acid
posit
domain
name
mutat
report
present
studi
show
virus
express
actual
grow
less
well
mous
lung
although
still
potent
inhibit
therefor
peptid
target
domain
expect
effect
merscov
strain
identifi
thu
far
potent
inhibit
merscov
infect
vitro
cell
cultur
significantli
acceler
viru
clearanc
deliv
merscov
challeng
present
studi
demonstr
mice
intranas
treat
alon
combin
hour
viral
challeng
viral
titer
lung
significantli
reduc
treat
group
complet
clearanc
observ
mice
treat
combin
figur
verifi
vivo
efficaci
prophylact
treatment
chose
deliv
intranas
mer
predominantli
respiratori
tract
infect
autopsi
surgic
specimen
avail
patient
mer
known
whether
clinic
relev
infect
occur
organ
furthermor
merscov
releas
apic
side
respiratori
tract
cell
therefor
peptid
deliv
intranas
would
maxim
site
infect
similarli
intranas
administr
combin
also
significantli
reduc
viral
titer
lung
mice
complet
viru
clearanc
treat
mice
figur
wherea
untreat
mice
unabl
clear
merscov
day
owe
lack
b
cell
addit
intranas
administr
combin
mice
hour
infect
significantli
reduc
viral
titer
inhibitortr
group
compar
pbstreat
mice
titer
reduc
mice
treat
combin
figur
patholog
chang
lung
perivascular
peribronchi
interstiti
infiltr
well
alveolar
septa
thicken
moder
reduc
group
treat
alon
signific
attenu
group
figur
unfortun
lung
sampl
avail
patient
therefor
known
whether
similar
find
would
present
infect
human
howev
base
studi
autopsi
specimen
patient
infect
sarscov
like
sever
ill
patient
would
exhibit
diffus
alveolar
damag
marmoset
anim
experiment
infect
merscov
develop
similar
diseas
sever
knowledg
wide
avail
anim
model
sever
diseas
develop
import
test
prophylact
therapeut
efficaci
may
also
necessari
evalu
differ
rout
administr
patient
experiment
infect
anim
shown
develop
signific
system
diseas
conclus
peptid
merscov
fusion
inhibitor
specif
target
protein
domain
highli
effect
inhibit
vitro
vivo
infect
diverg
merscov
strain
intranas
applic
especi
combin
show
high
efficaci
acceler
merscov
clearanc
anim
suggest
good
potenti
develop
prophylact
agent
protect
highrisk
popul
includ
healthcar
worker
famili
member
patient
infect
merscov
also
show
efficaci
treatment
mice
indic
potenti
use
therapeut
agent
treat
patient
